Datum | Källa | Rubrik | Typ | Alternativ |
---|---|---|---|---|
2023-07-10 | Nanexa | Sommarbrev från Nanexa | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-07-10 | Nanexa | Summer letter from Nanexa | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-06-09 | Nanexa | Bulletin from Nanexa’s Annual General Meeting 2023 | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-06-09 | Nanexa | Kommuniké från årsstämma i Nanexa | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-06-09 | Nanexa | Nanexa har slutfört den planerade rekryteringen till Fas 1-studien av NEX-20 | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-06-09 | Nanexa | Nanexa has completed the planned recruitment to the Phase 1 study of NEX-20 | Pressreleaser | Ladda ner | Visa Stäng |
Pressreleaser |
Nanexa has completed the planned recruitment to the Phase 1 study of NEX-20Nanexa AB today announced that the recruitment and dosing has been completed in the NEX-20 Phase 1 study. Since December last year, healthy volunteers have been administered single doses in three sequential escalating dose groups. Data on the pharmacokinetic profile, safety and tolerability is now being collected for the last dose group, and results are expected to be presented after the summer. “We are very happy to have completed the recruitment on time and we look forward to evaluating study results of NEX-20” says David Westberg, CEO of Nanexa. “I am very proud of our project team dedicated to deliver this study according to target timelines and generate high quality data for us to take the next step in the NEX-20 project. We know from discussions with our international advisory board that adherence to the prescribed treatment with lenalidomide can be suboptimal for some patients, and as more and more patients globally are treated with lenalidomide for a long time, we clearly see that there is an unmet medical need where we can help by providing a depot formulation like NEX-20.” NEX-20 is a long-acting formulation of lenalidomide based on Nanexa’s drug delivery system PharmaShell®. Lenalidomide is an immunomodulatory compound targeting both cancer cells and their microenvironment (1). Currently patients take lenalidomide daily as an oral capsule for 21-28 days in 28-day cycles. 1) A review of the history, properties, and use of the immunomodulatory compound lenalidomide Zeldis et al. Ann NY Acad Sci. 2011 Mar;1222:76-82 |
||||
2023-06-01 | Nanexa | Nanexa skriver kontrakt med internationellt ledande CRO inom diabetes för fas I-studie med NEX-22 | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-06-01 | Nanexa | Nanexa signs contract with leading international diabetes CRO for Phase I study with NEX-22 | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-05-22 | Redeye | Redeye: Nanexa - Moments of truth closing in | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-05-10 | Nanexa | Kallelse till årsstämma i Nanexa AB | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-05-10 | Nanexa | Notice of Annual General Meeting in Nanexa AB | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-05-05 | Emergers | Emergers: Equity Research | NANEXA: Solid progress in development into 2023, with funding needs on the horizon | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-05-04 | Nanexa | Nanexa publishes interim report for January – March 2023 | Rapporter | Ladda ner | Visa Stäng |
|
||||
2023-05-04 | Nanexa | Nanexa publicerar delårsrapport för januari-mars 2023 | Rapporter | Ladda ner | Visa Stäng |
|
||||
2023-05-03 | Nanexa | Nanexa publicerar årsredovisning för 2022 | Rapporter | Ladda ner | Visa Stäng |
|
||||
2023-05-03 | Nanexa | Nanexa publishes annual report for 2022 | Rapporter | Ladda ner | Visa Stäng |
|
||||
2023-03-23 | Nanexa | NEX-22 preclinical data shows controlled release of liraglutide for one month | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-03-23 | Nanexa | Prekliniska data av NEX-22 bekräftar kontrollerad frisättning av liraglutid i en månad | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-02-23 | Emergers | Emergers: NANEXA: 90 Second Pitch with CEO David Westberg | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-02-17 | Redeye | Redeye: Nanexa Q4 2022 - A Stronger Case | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-02-17 | Emergers | Emergers: Equity Research | NANEXA: Validation from Novo Nordisk positions Nanexa for an eventful year ahead | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-02-16 | Nanexa | Nanexa publishes year-end report for 2022 | Rapporter | Ladda ner | Visa Stäng |
|
||||
2023-02-16 | Nanexa | Nanexa publicerar bokslutskommuniké för 2022 | Rapporter | Ladda ner | Visa Stäng |
|
||||
2023-02-15 | Nanexa | Inbjudan till presentation av Nanexas bokslutskommuniké och Q4-rapport | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-02-15 | Nanexa | Invitation to presentation of Nanexa’s year-end report and Q4-report | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-02-08 | Nanexa | Nanexa participates at the 4th annual “Beyond Medicines’ Barriers Meeting”, arranged by the International Myeloma Foundation | Analyser | Ladda ner | Visa Stäng |
|
||||
2023-02-08 | Nanexa | Nanexa deltar på 4th annual “Beyond Medicines’ Barriers Meeting”, arrangerat av International Myeloma Foundation | Analyser | Ladda ner | Visa Stäng |
|
||||
2022-12-23 | Emergers | Emergers: Equity Research | NANEXA: Novo Nordisk deal offers both scientific validation and investor-friendly financing | Analyser | Ladda ner | Visa Stäng |
|
||||
2022-12-21 | Nanexa | Inbjudan till nyhetskommentar med anledning av Nanexas nyhetssläpp den 21 december 2022 | Analyser | Ladda ner | Visa Stäng |
|
||||
2022-12-21 | Nanexa | Invitation to commentary regarding Nanexa's press release on 21 December 2022 | Analyser | Ladda ner | Visa Stäng |
|
||||
2022-12-21 | Nanexa | Nanexa signs an exclusivity and evaluation agreement worth SEK 46.1 million and completes a directed share issue of SEK 17.2 million to Novo Nordisk | Analyser | Ladda ner | Visa Stäng |
|
||||
2022-12-21 | Nanexa | Nanexa tecknar ett exklusivitets- och utvärderingsavtal värt 46,1 MSEK och genomför en riktad emission till Novo Nordisk om 17,2 MSEK | Analyser | Ladda ner | Visa Stäng |
|
||||
2022-12-06 | Nanexa | Nanexa har startat Fas 1-studien med NEX-20 enligt plan | Analyser | Ladda ner | Visa Stäng |
|
||||
2022-12-06 | Nanexa | Nanexa has started the Phase 1 study of NEX-20 according to plan | Analyser | Ladda ner | Visa Stäng |
|
||||
2022-11-16 | Nanexa | Nanexa AB och VitriVax, Inc. har nått en lösning på patentintrångsprocessen | Analyser | Ladda ner | Visa Stäng |
|
||||
2022-11-16 | Nanexa | Nanexa AB and VitriVax, Inc. have resolved the patent infringement lawsuit | Analyser | Ladda ner | Visa Stäng |
|
||||
2022-11-14 | Nanexa | Nanexa receives approval to start clinical trial with NEX-20 | Analyser | Ladda ner | Visa Stäng |
|
||||
2022-11-14 | Nanexa | Nanexa erhåller godkännande att starta klinisk studie med NEX-20 | Analyser | Ladda ner | Visa Stäng |
|
||||
2022-11-10 | Nanexa | Valberedning inför Nanexa AB (publ) årsstämma 2023 | Analyser | Ladda ner | Visa Stäng |
|
||||
2022-11-10 | Nanexa | Nomination Committee for Nanexa AB (publ) Annual General Meeting 2023 | Analyser | Ladda ner | Visa Stäng |
|
||||
2022-10-26 | Emergers | Emergers: Equity Research | NANEXA: Charging to enter triple clinical trials in the coming year | Analyser | Ladda ner | Visa Stäng |
|
||||
2022-10-25 | Nanexa | Nanexa publishes interim report for January – September 2022 | Analyser | Ladda ner | Visa Stäng |
|
||||
2022-10-25 | Nanexa | Nanexa publicerar delårsrapport för januari-september 2022 | Analyser | Ladda ner | Visa Stäng |
|
||||
2022-10-24 | Nanexa | Inbjudan till presentation av Nanexas Q3-rapport 2022 | Analyser | Ladda ner | Visa Stäng |
|
||||
2022-10-21 | Nanexa | Nanexa tecknar utvärderingsavtal med läkemedelsbolag specialiserat inom ögonområdet | Analyser | Ladda ner | Visa Stäng |
|
||||
2022-10-21 | Nanexa | Nanexa signs evaluation agreement with a Speciality Pharma company | Analyser | Ladda ner | Visa Stäng |
|
||||
2022-09-27 | Nanexa | Nanexa AB och Vitrivax, Inc har nått en överenskommelse i alla väsentliga delar | Analyser | Ladda ner | Visa Stäng |
|
||||
2022-09-27 | Nanexa | Nanexa AB and Vitrivax, Inc reach agreement in principle | Analyser | Ladda ner | Visa Stäng |
|
||||
2022-09-19 | Emergers | Emergers: NANEXA Equity Research Case Video Summary | Analyser | Ladda ner | Visa Stäng |
|
||||
2022-09-16 | Emergers | Emergers: Equity Research | NANEXA: New project NEX-22 to add significant daily benefits for 50m patient market | Analyser | Ladda ner | Visa Stäng |
|
||||
2022-09-15 | Nanexa | Nanexa startar produktprojektet NEX-22 som adresserar en enorm marknad | Analyser | Ladda ner | Visa Stäng |
|
||||
2022-09-15 | Nanexa | Nanexa launches NEX-22 product project to address a huge market | Analyser | Ladda ner | Visa Stäng |
|
||||
2022-08-30 | Nanexa | Nanexa tecknar utvärderingsavtal med ett stort globalt läkemedelsbolag | Analyser | Ladda ner | Visa Stäng |
|
||||
2022-08-30 | Nanexa | Nanexa signs evaluation agreement with a Global Pharmaceutical Company | Analyser | Ladda ner | Visa Stäng |
|
||||
2022-08-29 | Redeye | Redeye: Nanexa - Our Q2 Comment | Analyser | Ladda ner | Visa Stäng |
|
||||
2022-08-26 | Nanexa | Nanexa publishes interim report for January – June 2022 | Analyser | Ladda ner | Visa Stäng |
|
||||
2022-08-26 | Nanexa | Nanexa publicerar delårsrapport för januari-juni 2022 | Analyser | Ladda ner | Visa Stäng |
|
||||
2022-08-25 | Nanexa | Nanexa receives extended GMP-certificate for the new pilot plant | Analyser | Ladda ner | Visa Stäng |
|
||||
2022-08-25 | Nanexa | Nanexa erhåller utökat GMP certifikat för den nya pilotanläggningen | Analyser | Ladda ner | Visa Stäng |
|